Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-29

Serine proteinase inhibitors for therapy of inflammatory skin diseases

Cel

Currently, no specific and causative therapy for the treatment of inflammatory skin diseases, e.g. atopic dermatitis and psoriasis, is available. To create new treatment options for these diseases, the applicants plan a strategic partnership by the mutual exchange of knowledge. Both the industrial partner, IPF PharmaCeuticals (Hannover, Germany), and the academic partner, Centro de Investigaciones Biologicas (Madrid, Spain), will contribute to the know-how transfer in the field of applied protein research for the examination of newly discovered serine proteinases and their inhibitors. A multi-domain serine proteinase inhibitor (LEKTI) was identified and was shown to play a significant role in the development of skin diseases.

Based on these findings, the proposed research aims to examine the (patho-)physiological role of relevant serine proteinases and their pertinent inhibitors for the discovery of new drugs against skin diseases. The cooperation between the German company and the institution from the Spanish Council of Scientific Research (CSIC) will result in a long-lasting strategic partnership taking advantage of complementary know-how of each organization and of the different scientific and economic networks in these two countries of the EC.The applicants have a long-standing experience in the organization of scientific research collaborations, workshops, execution of scientific grants, publications, patent issues and in the exploition of intellectual property rights.

This research co-operation plans (i) to identify and produce serine proteinases and their inhibitors related to atopic dermatitis and psoriasis, (ii) to elucidate their three-dimensional structure, (iii) on the basis of this knowledge to design optimized inhibitors, and (iv) to test the pharmacological potential of the inhibitors in animal models for skin diseases.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Temat(-y)

Zaproszenie do składania wniosków

FP6-2002-MOBILITY-3
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

TOK - Marie Curie actions-Transfer of Knowledge

Koordynator

IPF PHARMACEUTICALS
Wkład UE
Brak danych
Koszt całkowity
Brak danych

Uczestnicy (1)